Evidence map›Paper›PMID 41709763›Full record

ArticleSmall (Weinheim an der Bergstrasse, Germany)2026

Gold@MnFe-Prussian Blue Analog Yolk@Shell Nanoparticles for Light-Triggered and pH-Sensitive Drug Release.

Shoaib Azeem, Javier Alda-Gómez, Roger Sanchis-Gual, Marc Coronado-Puchau, Eugenio Coronado Miralles

Abstract read
In one paragraph

Article in Small (Weinheim an der Bergstrasse, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shoaib AzeemInstituto de Ciencia Molecular, Universitat De València, Paterna, Spain.ORCID https://orcid.org/0000-0003-1523-8700
Javier Alda-GómezInstituto de Ciencia Molecular, Universitat De València, Paterna, Spain.
Roger Sanchis-GualInstituto de Ciencia Molecular, Universitat De València, Paterna, Spain.ORCID https://orcid.org/0000-0002-9096-7930
Marc Coronado-PuchauInstituto de Ciencia Molecular, Universitat De València, Paterna, Spain.ORCID https://orcid.org/0000-0002-2669-8748
Eugenio Coronado MirallesInstituto de Ciencia Molecular, Universitat De València, Paterna, Spain.ORCID https://orcid.org/0000-0002-1848-8791

Funding

European Union PID2023-149309OB-I00Generalitat Valenciana PROMETEO/2024/051Ministerio de Ciencia, Innovación y Universidades CEX2019-000919-MMinisterio de Ciencia, Innovación y Universidades MFA/2022/050Ministerio de Ciencia, Innovación y Universidades PRE2019-089414
6 · The paper itself

Abstract

Yolk@shell nanostructures have emerged as promising platforms for biomedical applications due to their unique architecture, which combines the high surface area and loading capacity of hollow nanoparticles with the structural stability and functional versatility of core@shell systems. In this work, we report the synthesis of multifunctional Au@MnFe-Prussian Blue Analog (PBA) yolk@shell nanostructures through a two-step process: initial formation of Au@PBA core@shells, followed by selective leaching of the inner PBA shell. This process not only generates a well-defined internal cavity of ∼75 nm, enhancing drug-loading capacity, but also induces partial etching of the gold core and its redeposition onto the PBA shell. This redistribution of gold leads to the emergence of absorbance in the near-infrared (NIR) region, enabling efficient photothermal conversion. Meanwhile, the MnFe PBA shell offers pH-sensitive properties and excellent biocompatibility. Using doxorubicin (DOX) as a model chemotherapeutic, the system exhibits a loading efficiency of ∼50% and a pH-dependent release profile, with enhanced release (∼150%) under NIR irradiation. In vitro studies demonstrate effective cellular uptake and synergistic cytotoxicity upon combined chemo- and photothermal treatment. This study reveals the significant potential of Au@MnFe PBA yolk@shell architectures for controlled drug delivery.

Indexed as

Drug LiberationFerrocyanidesGoldLightMetal NanoparticlesNanoparticlesDoxorubicinHumansHydrogen-Ion ConcentrationDoxorubicinferric ferrocyanideFerrocyanidesGolddrug deliverygoldnanoparticlesPrussian Blue Analogsyolk@shell

Identifiers

PMID41709763
PMCPMC13054203

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.